BEV specifically blocks VEGF, inhibits the formation of new blood vessels, and destroys existing neovascularization network, so as to normalize tumor blood vessels and facilitate the release of CT drugs into tumor to play its cell-killing role; BEV can also inhibit the complementation of endothelial stem cells, improve the environment of tumor hypoxia, to reduce the stimulation of VEGF secretion, thereby inhibiting the formation of new blood vessels (Ferrara et al., 2003). This evidence concerns the gene VEGFA and neoplasm.